 BEDMER, N.J.--BUSINESS WIRE--TYME Technologies, Inc. Nasdaq: TYME the Company or TYME, an emerging biotechnology company developing cancer metabolism-based therapies CMBTsTM, announced financial and operating results for its fiscal first quarter ended June 30, 2021. Fiscal First Quarter 2022 Business and Recent Highlights: Completed strategic review and identified clinical priorities with a focus on metastatic hormone receptor positive, human epidermal growth factor receptor 2 ne 